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Background: Immortalized cancer cell lines are now well-established procedures in biomedicine for a more
complete understanding of cellular processes in cancer. However, they are more useful in preparation of fresh
tumour tissue, in order to obtain cancer cells with highly preserved individual tumour properties. In the present
study we report an analytical investigation on a breast cancer primary cell culture isolated from a surgical specimen
obtained from a patient with an infiltrating ductal carcinoma. The objective of the research was to reveal
unrecognized aspects of neoplastic cells, typical of the tumour from where the cells were derived, but masked in
fixed tissue sections, in order to better predict the aggressive potentiality of the tumour.
Findings: Using a combination of mechanical and enzymatic treatment, the tumour tissue was dissociated
immediately after surgical removal. The primary cells were isolated by differential cell centrifugation and grown in
selective media. Immunocytochemistry and quantitative RT-PCR analysis were performed to detect the presence of
specific biomarkers at protein and transcript level.
The isolated primary breast cancer cells displayed phenotypic behaviour, characteristic of malignant cells and
expression of several mesenchymal markers, revealing a strong signature for the epithelial-to-mesenchymal
transition associated to a stellate morphology with a number of cellular protrusions and the attitude to overgrow
as multilayered overlapping cellular foci.
Conclusions: Our data are a further meaningful indication that primary cell cultures represent a powerful system
that could be applied to those cases deserving a deeper investigation at molecular level in order to design
individualized anticancer therapies in the future.
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Breast cancer recovery has increased in recent years,
thanks to the efforts of research in this field. However,
despite the important results obtained, breast cancer
remains a complex multifactorial pathology, hard to de-
scribe comprehensively and therefore difficult to treat ap-
propriately. Indeed, several subtypes of breast carcinoma
have been acknowledged with different clinical outcomes
and therapeutic responses. Histological and molecular
classification of breast cancer have revealed at least four
major subgroups: 1) basal-like: estrogen receptor-negative* Correspondence: luigi.minafra@polooncologicocefalu.it
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reproduction in any medium, provided the or(ER-), progesterone receptor-negative (PR-), HER2-
negative (HER2-); 2) luminal A: estrogen receptor-positive
(ER+, low grade); 3) luminal B: ER+, high grade; 4) HER2-
positive (HER2+) [1]. All these subgroups generally corres-
pond to different patients’ prognoses and responsiveness
to therapy. The HER2+ and basal-like phenotypes, for ex-
ample, exhibit poor prognosis and resistance to therapy,
although the HER2+ subgroup is usually responsive to tar-
geted therapy with Herceptin. The basal-like tumours
show higher initial responses to neoadjuvant chemothera-
pies [2,3], but show preferential relapse to the brain and to
the lung [4,5]. However, these parameters appear still in-
sufficient to give a reliable prevision of the clinical out-
come of the individual patient.
A critical point is the prediction of the metastatic
potentiality of a tumour. The metastatic project of aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Representative histological section of the resected IDC
tumour sample (H&E, 20x). Calibration bar: 30 μm.
Figure 2 Light micrographs of the non-tumorigenic MCF-10A
epithelial breast cell line immunostained for the epithelial
marker panCK (20x). Calibration bar: 30 μm.
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origin, start to detach from the tissue boundaries, lose
polarity, the stationary phenotype and acquire motile
capability. This process is defined as ‘epithelial-to-
mesenchymal transition’ (EMT) and has been described in
the past in the morphogenetic events during development.
Only more recently, during the 90’s, has EMT been recog-
nized as an instrument for neoplastic cell invasion and me-
tastasis production, including breast cancer cells [6-9].
However, evidence to demonstrate the existence of EMT
in vivo has been controversial. This is because histological
preparation of ex-vivo tissues is not sufficiently adequate to
reveal the molecular and immunological traits of EMT. To
overcome these limitations, cultivation of primary cells
from individual breast cancer tissues is a fundamental ap-
proach for the in vitro study of a wide variety of neoplastic
cell properties. In addition, primary cells mimic more
closely the in vivo behaviour, as compared to the immorta-
lized breast cancer cell lines. On the other hand, the pro-
cedure of isolation and the maintaining of primary cells in
culture is a good strategy that could be used for those cases
deserving a deeper investigation at molecular level to
designing anticancer therapies. Here, we report the analyt-
ical investigation of a neoplastic cell population isolated
from an infiltrating ductal carcinoma (IDC) of the breast.
These cells revealed phenotypic traits of a malignant
behaviour such as a stellate morphology, cytoplasmic
protrusions, multilayered growth in the absence of contact
inhibition and expression of several mesenchymal bio-
markers, displaying a strong signature for the epithelial-to-
mesenchymal transition. The follow up of the patient was
not part of this study.
Materials & methods
Tissue sample
An extra portion of tissue of an IDC of the breast, unneces-
sary for histological diagnosis after surgery, was obtained
for this study. The patient gave a written informed consent
to research partecipation according to the Helsinki Declar-
ation and the study was approved by the Ethical Committee
of the San Raffaele G. Giglio Hospital, Cefalù (number of
protocol: C.E.2012/16). A representative hematoxylin and
eosin (H&E) stained section of the resected tumour is
shown in Figure 1.
Cell culture
The breast tissue was disaggregated mechanically imme-
diately after surgery and then digested overnight at 37°C
with a mixture of 1 mg/ml collagenase type I (Invitro-
gen) and 100 U/ml hyaluronidase (Sigma) in DMEM
containing 100 U/ml penicillin and 100 μg/ml strepto-
mycin. DMEM medium and antibiotics were purchased
from Invitrogen. Cells were then recovered by differen-
tial centrifugation method modified by Speirs et al. [10].The breast cancer primary cells, named BCpc, were cul-
tured in a selective medium and grown at 37°C under 5%
CO2-95% air atmosphere in a humidified incubator. The
medium composition was the following: DMEM with anti-
biotics supplemented with 10 mM Hepes (Invitrogen) and
1 mg/ml bovine serum albumin (BSA), 10 ng/ml cholera
toxin, 0.5 μg/ml hydrocortisone, 5 μg/ml insulin, 5 ng/ml
epidermal growth factor (EGF), 5 μg/ml apo-transferrin (all
from Sigma).
For qRT-PCR experiments, the non-tumorigenic breast
epithelial MCF-10A cell line, expressing the epithelial mar-
ker pancytokeratin (panCK) was used as control (Figure 2)
and cultured according to ATCC instructions.
Immunocytochemistry (ICC)
To conduct the ICC analysis the breast cancer primary
cells (BCpc) were grown on slides until the cells were at
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formed using methanol-based buffered preservative solu-
tion (ThinPrep PreservCyt Solution) according to the
manufacturer’s instructions. ICC analysis was carried out
using the Ventana Benchmark automated staining sys-
tem and the propietary reagents, unless otherwise speci-
fied. Endogenous peroxidase activity was blocked
utilizing the Ventana inhibitor in the kit. Incubation with
primary antibody was carried out at 37°C for 30 minutes
followed by washing with PBS (Phosphate-Buffered
Saline). The site of the antigen was visualised with
RocheVentana’s Ultra View DAB kit. The cells were
counterstained with Ventana Haematoxylin and blued
with Ventana Blueing Solution. On completion of stain-
ing, the cells were dehydrated in alcohol, cleared in Xy-
lene and mounted in synthetic resin. Negative controls,
where the primary antibody was excluded, confirmed the
specificity of immunostaining. Roche Ventana primary
antibodies were used to detect all selected markers, ex-
cept Ki-67/Mib-1 (DakoCytomation), EGFR (Zymed La-
boratories), and CD44 (Neomarkers), according to the
manufacturer’s instructions.RNA extraction and quantitative RT-PCR analysis
Total RNA was extracted from the BCpc and MCF-10A
cells utilizing TRIzol reagent according to the manufac-
turer’s specifications (Invitrogen). RNA concentration was
determined by spectrophotometry. One μg of total RNA
was reverse-transcribed into cDNA with SuperScriptII re-
verse transcriptase (Invitrogen) and 0.5 μg oligo(dT) in a
final volume of 20 μL. One μL of cDNA (50 ng RNA
equivalent) was analysed by Real-Time PCR (1 cycle 95°C
for 20 sec and 40 cycles of 95°C for 3 sec, 60°C for 30 sec)Table 1 The sequences of primers selected to perform qRT- P
Gene Name GenBank For
ACTA2 (α-SMA) NM_001141945.1 5′-g
CDH1 (E-cadherin) NM_004360.3 5′-c
CDH2 (N-cadherin) NM_001792.3 5′-g
FN1(Fibronectin 1) NM_212482.1 5′-g
KRT5 (CK5) NM_000424.3 5′-t
KRT6 (CK6) NM_005554.3 5′-c
KRT8 (CK8) NM_002273.3 5′-g
KRT18 (CK18) NM_000224.2 5′-c
RN18S1(rRNA18S) NR_003286.2 5′-a
SNAI1 (Snail) NM_005985.3 5′-g
TGFβ1 NM_000660.4 5′-c
Twist1 NM_000474.3 5′-a
VIM (vimentin) NM_003380 5′-a
ZEB1 NM_001128128.2 5′-g
ZEB2 NM_014795.3 5′-ain triplicate using Fast 7500 Real-Time PCR System (Ap-
plied Biosystems). Amplification reactions were performed
in a 20 μl reaction volume containing 10 pmoles of each
primer and the Fast SYBR Green Master Mix according to
the manufacturer’s specifications (Applied Biosystems).
Reaction specificity was controlled by post-amplification
melting curve analysis. The oligonucleotide primers were
selected with Primer3 software (http://fokker.wi.mit.edu/
primer3) and tested for their human specificity using
NCBI database. Primers sequence (forward and reverse)
used are listed in Table 1. Quantitative data, normalized
versus rRNA 18S gene, were analysed by average of tripli-
cates Ct (cycle threshold) according to the 2-ΔΔct method
using SDS software (Applied Biosystems). The data shown
were generated from three independent experiments and
the values are expressed relative to mRNA levels in the
non-tumorigenic breast epithelial MCF-10A control cells
as mean±SD.Findings
Isolation and in vitro expansion of primary cells from the
breast tumour specimen
Primary tumour cells were isolated from breast tissue
of a patient with an infiltrating ductal carcinoma
(IDC) and with the following histologic features: mod-
erately differentiated, G2, pT2, pN1a, MIB-1 (KI-67)
proliferation index 21%, ER+/PR+, HER2-. The tissue
was disaggregated mechanically immediately after sur-
gery and the cells were isolated by applying enzymatic
digestion with collagenase/hyaluronidase and differen-
tial centrifugation method [10]. Following enzymatic
treatment and culture in selective media, the breast
cancer primary cells (BCpc) started to move away fromCR analysis
ward primer Reverse primer
ctgttttcccatccattgtg-3′ 5′-ttggtgatgatgccatgttct-3′
caagtgcctgcttttgatga-3′ 5′-cccctacccctcaactaac-3′
acaatgcccctcaagtgtt-3′ 5′-ccattaagccgagtgatggt-3′
gaaagcatatgcagccaac-3′ 5′-ctacagtattgcgggccaga-3′
ttgtctccaccacctcctc-3′ 5′-cctgggaaccaaagaatgtg-3′
aagctcaccttccaggact-3′ 5′-gagtgtgagaggctggagga-3′
ggaagctggtgtctgagtc-3′ 5′-ctcctgttcccagtgctacc-3′
cagtctgtggagaacgaca-3′ 5′-atctgggcttgtaggccttt-3′
aacggctaccacatccaag-3′ 5′-caattacagggcctcgaaag-3′
cgagctgcaggactctaat-3′ 5′-ggacagagtcccagatgagc-3′
cctggacaccaactattgc-3′ 5′-aggcagaagttggcatggta-3′
aactggcctgcaaaaccatag-3′ 5′-tgcattttaccatgggtcctg-3′
acaaccgacactcctacaaga-3′ 5′-tggttggatacttgctggaaa-3′
aaaaaccacaaggggatgag-3′ 5′-gcttgactttcagccctgtc-3′
tggggccagaagccacgat-3′ 5′-gtcgactgcatgaccatcgc-3′
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Figure 3 shows a panel of phase-contrast micrographs
of cell culture fields at different growth stages: the ini-
tial phase of cell spreading from the tissue after 7 days
in culture (Figure 3A); a field of fully dissociated cells
after 15 days (Figure 3B); a detail of cells at the 4th
passage manifesting the stellate morphology and a
number of cellular protrusions, or spikes (Figure 3C);
within 24-48 hrs in the culture, the cells at the 4th
growth passage were fully widespread, adjoined to each
other and overgrown in scattered dense foci of multi-
layered overlapping cells (Figure 3D).
Immunological characterization
Cells were cultured for 4 passages and then assayed to
test the expression of known breast cancer biomarkers.C D
A
Figure 3 Phase-contrast micrographs of breast cancer primary cells (B
spreading from the tissue after 7 days in culture (10x). B. 15-day culture sh
4th growth passage showing the stellate morphology and cellular protrusio
hrs in culture (10x). Calibration bars: 30 μm.The ICC analysis revealed a complex immunological pat-
tern that did not fall into the major subtypes. A panel of
micrographs of ICC images of BCpc grown on slides
and incubated with the proper antibody is reported in
Figure 4. Based on immuno-staining intensity, the reac-
tion was classified as positive for vimentin, alpha-smooth
muscle actin (α-SMA), EGFR, Ki-67, and for stem cell
marker CD44 (Figure 4A-F); weakly positive for pancyto-
keratin (panCK), luminal CK8/18, and for basal-like
markers p53, p63 and c-kit (Figure 5A-E); negative for
basal CK5/6, HER2, ER and PR (Figure 6A-D). While the
cytokeratin reaction was rather faint, the SMA and in
particular, vimentin staining was very intense and its
localization made it possible to appreciate the long cell
projections, frequently making contacts between one cell
and the neighbouring one. In addition, from the tip ofB
Cpc) at different stages of the culture. A. Initial phase of cell
owing the cells fully dissociated (20x). C. A detail of the culture at the
ns (spikes) (20x). D. The cells forming multilayered foci within 24-48
A B
C D
E F
G H I L M
Figure 4 Light micrographs of BCpc immunostained for A. vimentin (25x) and B. (50x); C. SMA (25x); D. EGFR (25x); E. Ki-67 (25x); F.
CD44 (25x). Calibration bars: 30 μm. Cropped areas of representative fields of negative controls for: G. vimentin, H. SMA, I. EGFR, L. Ki-67, M. CD44.
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Figure 5 Light micrographs of BCpc immunostained for A. panCK (25x); B. CK8/18 (50x); C. p53 (25x); D. p63 (25x); E. c-kit (25x).
Calibration bars: 30 μm. Cropped areas of representative fields of negative controls for: F. panCK, G. CK8/18, H. p53, I. p63, L. c-kit.
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C D
Figure 6 Light micrographs of BCpc immunostained for A. CK5/6 (25x); B. HER2 (25x); C. ER (25x); D. PR (25x). Calibration bars: 30 μm.
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of vesicles, putative exosomes (Figure 4B). These data
were indicative of a strong signature for the epithelial-
to-mesenchymal transition.
Transcriptional analysis
To test if the observed phenotypic and immuno-
logical traits of the BCpc could be reconducted to
the epithelial-mesenchymal transition, quantitative
RT-PCR (qRT-PCR) analyses were performed in parallel
with non-tumorigenic mammary epithelial MCF-10A
cells, used as a normal control for in vitro studies of breast
cancer [11,12]. The genes selected were some of the most
representative targets of the TGF-β signal transduction
pathway, as well as the cytoskeleton and adhesion pro-
teins, the downstream targets of the pathway [13,14]. Rela-
tive to the non-tumorigenicMCF-10A cells, in the BCpc
we observed a significantly increased expression of tran-
scriptional levels of TGF-β1 gene (~6.8-fold), a major in-
ducer of the EMT (Figure 7A). Moreover qRT-PCRanalysis revealed an increase of mRNA levels of some
transcriptional factors, which are the master regulators of
EMT. In particular, Twist was 20.9-fold higher, Snail 11.4-
fold, and Zeb1 and Zeb2 3.2-fold and 6.8-fold, respectively,
suggesting an induction of these factors by TGF-β signal-
ling pathway. Since all these genes contribute to transcrip-
tional repression of the E-cadherin gene (CDH1), as
expected, BCpc showed a downregulation of this gene
(Figure 7A). In addition, the BCpc expressed high levels of
the mRNAs which encode mesenchymal markers, the final
targets activated by the TGF-β pathway, specifically N-
cadherin (CDH2, ~8.2-fold), Vimentin (VIM, ~36.5-fold),
Fibronectin (FN1, ~11-fold), and α-SMA (ACTA2, ~28-
fold), which contribute to the establishment of the motile
and invasive cell phenotype (Figure 7B). As the induction
of mesenchymal factors by the TGF-β is associated with
the downregulation, beyond the E-cadherin, of various
epithelial factors including several keratins [12], we also
assayed the expression of Cytokeratin 8 (KRT8), 18
(KRT18), 5 (KRT5) and 6 (KRT6A) genes in the BCpc.
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Figure 7 BCpc express multiple genes associated with an
epithelial mesenchymal transition as determined by qRT-PCR.
The gene expression data are relative to the mRNA levels in MCF-
10A control cells and are mean± SD of three independent
experiments (***p< 0.001, **p< 0.01, *p< 0.05, all versus control
cells).
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of transcriptional levels of all these genes in our cellular
system (Figure 7C).
In general, these data indicate that the BCpc
expressed multiple genes associated with an epithelial-
mesenchymal transition.
Discussion
The application of cell culture to the clinical research
has received great impulse in recent years with the ac-
knowledgement that cells derived from different normal
and tumorous tissues are able to maintain most of their
proper phenotypic traits, as a memory of their origin, es-
pecially the primary cells cultures. In addition, primary
cultures represent a powerful system to study cellbehaviour and cellular pathways. It is well documented
that epithelial cells derived from normal tissues maintain
in culture a polarized stationary phenotype and show
contact inhibition during proliferation. On the contrary,
cancer cells usually display non-polarized cell morph-
ology, reduction or absence of intercellular contacts and
a motile attitude which is typical of mesenchymal cells.
The aim of this study was to identify phenotypic traits
and molecular markers in primary cell culture derived
from a patient with IDC of the breast, useful to evaluate
risk of tumour progression in vivo. After tumour tissue
dissociation and cell spreading, the totality of viable cells
displayed the characteristic features of malignant cells:
that is a markedly irregular morphology, often of a stel-
late aspect with extensive cellular protrusions. Immuno-
cytochemistry assays revealed a complex immunological
pattern. The majority of cells were negative for HER2
and for estrogen and progesterone receptors, as
expected for cells undergoing EMT [15]. Moreover, the
cells were weakly positive for the basal-like biomarkers
p53, p63 and c-kit, and generally positive for EGFR, Ki-
67 and for stem cell marker CD44.
Concerning the cytoskeleton proteins, the cells were
weakly positive for pancytokeratin (panCK), that repre-
sents a general marker for cells of epithelial origin, also
weakly positive for the luminal cytokeratins (CK8/18)
and negative for the basal ones (CK5/6). On the con-
trary, all cells were strongly positive for vimentin, the
mesenchymal cytoskeletal protein, and for the alpha-
smooth muscle actin (α-SMA). These results well sup-
port the occurrence of the phenotypical EMT process in
the cells of our study. To reinforce this hypothesis, a fur-
ther set of investigations were conducted in order to
evaluate the transcription levels of the already detected
biomarkers and to expand the panel of candidate genes,
by the use of qRT-PCR. Literature data report that dif-
ferent pathways are expected to control the EMT during
tumour growth, in the first place the TGF-β-driven cas-
cade [13,14]. It is now generally accepted that elevated
TGF-β level is suppressive during the early phase of
tumour outgrowth, while at later stages it amplifies ma-
lignant conversion and tumour progression. Consistent
with the response to TGF-β, the majority of breast
tumours, including their metastases, are positive for nu-
clear factors activated by TGF-β signalling pathway [16-
19]. In addition, TGF-β is reported to promote resistance
to apoptosis, as well as to induce and initiate the EMT
cascade [20]. Interestingly, in our system we found a 6.8-
fold increase of TGF-β1 mRNA level with respect to the
non-tumorigenic control cells. Concurrently, the tran-
scription factors downstream of Smad, i.e. Twist, Snail,
Zeb1 and Zeb2 were increased several fold in compari-
son to the control cells, indicating an active transcrip-
tion of factors involved in the TGF-β signalling pathway.
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repression of E-cadherin, whose down-regulation pro-
gressively causes cell detachment and the loss of the
apico-basal polarity [13,14].
What appeared confirmatory of the TGF-β pathway in
our study was the down-regulation of the E-cadherin
transcription gene coupled with a significant increment
of the N-cadherin expression.
It is known that in breast cancer progression the loss of
E-cadherin–based cell adhesion is an important factor in
tumour invasiveness and that an over-expression of another
adhesion molecule, the N-cadherin, is associated with an
increased invasive potential of tumour cells [21-25]. More-
over, N-cadherin contributes to induce a mesenchymal-
scattered phenotype associated with reduced E- and
P-cadherin levels in squamous cell carcinoma and to pro-
mote breast cancer cell migration, invasion and metastasis
[26-30]. In our case, the hypothesis of the EMT occurrence
was further validated by the observed transition in the cyto-
skeleton assembly. Indeed, in addition to cytokeratin down-
regulation a net increment of vimentin transcription
appeared, together with the ACTA2 (α-SMA) and fibronec-
tin. A remarkable observation was the radiating immune-
reaction of vimentin from the perinuclear area to the tip of
long cytoplasmic protrusion, correlating with the dramatic
cell changes from epithelial to mesenchymal shapes and
from stationary to motile phenotype, as also decribed by
other Authors [6]. Besides the classical role of cytoskeletal
protein, recent studies have attributed several key functions
to the vimentin, which now appears to be an organizer of a
number of critical functions involved in attachment, migra-
tion, and ramification of cell signalling into several aspects
of cell physiology and pathology [31-33]. In addition,
vimentin is also considered as a novel potential anti-cancer
therapeutic target [34].
Our results and literature data, support the idea that
the full manifestation of the invasive properties of
tumour cells is accomplished when cells are fully
detached from the neighbouring ones, losing cell-cell
and cell-matrix interactions. These described changes
are indicative of an epithelial-to-mesenchymal transition
which represents a terminal point of a cascade of events,
at transcriptional and translational level, inducing severe
derangement of the original tissue architecture and a re-
programming of the neoplastic phenotypes. The EMT
phenomenon is difficult to predict in its dynamic evolu-
tion inside tissue sections, while the application of pri-
mary culture is a way to unmasking all the process.
Conclusion
As reported, we suggest that tissue dissociation and cul-
turing of primary cells after surgical removal of the
tumour offer great possibilities to investigate malignant
potentiality of tumour cells in addition to those that thetissue section may provide. We trust that this study may
offer a basis for further characterization of the molecular
mechanisms of breast cancer progression and for design-
ing individualized anticancer therapies in the future.
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